This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.08% per year. These returns cover a period from January 1, 1988 through May 6, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Bristol-Myers (BMY) Q2 Earnings, Sales Beat on Eliquis, Opdivo
by Zacks Equity Research
Bristol-Myers (BMY) earnings and sales beat estimates in the second quarter of 2022 on the back of Eliquis and Opdivo and a lesser decline in sales of Revlimid.
Alkermes (ALKS) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Alkermes (ALKS) delivered earnings and revenue surprises of 50% and 1.13%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Is a Beat Likely for DexCom (DXCM) This Earnings Season?
by Zacks Equity Research
DexCom's (DXCM) second-quarter results are likely to reflect rising global awareness of its real-time CGM.
Philips' (PHG) Q2 Earnings Down on Supply Chain Constraints
by Zacks Equity Research
Koninklijke Philips' (PHG) Q2 top and bottom-line results reflect the negative impact of supply chain constraints and COVID lockdowns in China.
Drug, Biotech Stocks' Q2 Earnings on Jul 27: BMY, GSK & More
by Zacks Equity Research
Let's look what is in store for the four drug, biotech companies slated to release quarterly results tomorrow- BMY, GSK, ALKS, TEVA
Ecolab's (ECL) Q2 Earnings & Revenues Beat Mark, Margins Down
by Zacks Equity Research
Ecolab's (ECL) robust performance across all of its segments drives its Q2 sales, despite business challenges.
Bristol-Myers (BMY) to Post Q2 Earnings: What is in the Cards?
by Zacks Equity Research
Investors will likely focus on the demand for Eliquis and Opdivo along with incremental contribution from newer drugs when Bristol-Myers (BMY) reports Q2 results. Operating expenses might have jumped.
Is a Beat in Store for Alkermes (ALKS) This Earnings Season?
by Zacks Equity Research
Alkermes' (ALKS) second-quarter 2022 results set to report earnings and revenues figures and provide updates on its portfolio of marketed drugs.
Gilead (GILD) Gets Positive CHMP Opinion for Veklury & Tecartus
by Zacks Equity Research
Gilead (GILD) receives positive CHMP opinion for full marketing authorization of its COVID-19 Jab, Veklury, and for using its CAR-T cell therapy Tecartus to treat relapsed or refractory B-cell precursor ALL in adults.
Baxter (BAX) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Baxter's (BAX) second-quarter results are likely to reflect growth in its Medication Delivery and BioPharma Solutions businesses. Hillrom's products are likely to have boosted sales
DaVita (DVA) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Supply constraints, along with inflationary pressures, is likely to have weighed on DaVita's (DVA) second quarter's top line.
What's in Store for West Pharmaceutical (WST) in Q2 Earnings?
by Zacks Equity Research
West Pharmaceutical's (WST) second-quarter results are likely to reflect strength in the Proprietary Products business.
Roche (RHHBY) 1H22 Earnings, Sales Grow, View Disappoints
by Zacks Equity Research
Roche (RHHBY) performance in the first half was decent on demand for its diagnostics base business and new drugs. Demand for COVID-19 tests is likely to fall in the second half.
Vascular Biogenics (VBLT) Down, Ovarian Cancer Study Fails
by Zacks Equity Research
Vascular Biogenics' (VBLT) phase III OVAL study, evaluating ofra-vec in patients with platinum-resistant ovarian cancer, fails to meet the primary endpoint.
Ecolab (ECL) to Report Q2 Earnings: What's in the Offing?
by Zacks Equity Research
Ecolab's (ECL) second-quarter results are likely to reflect continued strength in its Global Industrial segment.
Stryker (SYK) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Stryker's (SYK) second-quarter results are likely to reflect strong segmental performances. However, the resurgence of COVID-19 infections is likely to have hurt sales growth.
3 Stocks With Momentum Anomaly to Buy on Solid Earnings Rally
by Supriyo Bose
Alkermes plc (ALKS), BancFirst (BANF) and ExlService (EXLS) are currently witnessing a short-term pullback in price. So, make sure you take full advantage of it.
Sorrento (SRNE) Rises on FDA IND Clearance for COVID Drug
by Zacks Equity Research
Sorento Therapeutics (SRNE) receives IND application clearance from the FDA for a phase I study evaluating STI-1558 for COVID-19.
Alkermes (ALKS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Alkermes (ALKS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Incyte (INCY) Gets FDA Nod for Label Expansion of Opzelura
by Zacks Equity Research
Incyte (INCY) Opzelura cream 1.5% gets FDA approval for another indication - nonsegmental vitiligo in adult and pediatric patients 12 years of age and older.
Novartis (NVS) Q2 Earnings Beat, Revenues Miss Estimates
by Zacks Equity Research
Novartis (NVS) reports mixed results in the second quarter, as key brands maintain momentum but generic competition remains a drag.
Roche (RHHBY) Announces 2-Year Data on Vabysmo for nAMD
by Zacks Equity Research
Roche's (RHHBY) new two-year data reinforce the long-term efficacy, safety and durability of Vabysmo in wet age-related mtacular degeneration.
NexImmune (NEXI) IND Gets Clearance for HPV-Related Cancer Drug
by Zacks Equity Research
NexImmune (NEXI) gets FDA clearance for IND for drug for human papillomavirus (HPV)-related cancers.
Pluristem (PSTI) Phase III Study Misses Goal, Stock Down
by Zacks Equity Research
Pluristem (PSTI) phase III study of muscle regeneration following hip fracture surgery evaluating PLX-PAD cells did not meet the primary endpoint. Consequently, the stock declines.
Can Alkermes (ALKS) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Alkermes (ALKS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.